Skip to content

Glioma Susceptibility 1 C2750850

Published: July 22, 2026Updated: August 25, 2026

An inherited condition increasing risk of developing gliomas, a type of brain tumor. Family history is a key risk factor. Regular monitoring is recommended for early detection.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
oncologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Persistent headache

!

New-onset seizures

!

Cognitive decline

Generalized symptoms

(oncologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Personality changes

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Maximal Safe Surgical Resection

Aggressive but neurosurgically safe tumor resection to achieve maximal cytoreduction while preserving neurological function. Extent of resection is a key prognostic factor for outcomes.

surgical
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Radiation Therapy

Focused radiation treatment targeting residual tumor cells following surgery, with modern techniques like proton beam therapy minimizing damage to surrounding healthy brain tissue.

procedure

Additional treatment options

Temozolomide Chemotherapy

Alkylating agent chemotherapy used as part of combined modality treatment, shown to improve outcomes when combined with radiation in high-grade glioma protocols.

medication

Serial Neuroimaging Surveillance

Regular MRI imaging to monitor treatment response, detect recurrence early, and assess for treatment-related changes including pseudoprogression and radiation necrosis.

monitoring

Integrative Supportive Care

Adjunctive therapies including acupuncture for pain management, massage for symptom relief, and mind-body practices to support quality of life during intensive cancer treatment.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Glioma Susceptibility 1 C2750850?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Glioma Susceptibility 1 C2750850. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy